Biological Therapy in Psoriasis: Recognizing the Value

Slides:

Advertisements

Similar presentations

Gerald G Krueger MD Professor, Benning Presidential Endowed Chair

Advertisements

EXPRESS: Response Rates at Week Placebo (n=77) Infliximab 5 mg/kg (n=301) Per cent of patients Per cent of patients with.

C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.

1 Agenda  Overview –Burt Adelman MD  Efficacy and Pharmacodynamics –Akshay Vaishnaw MD, PhD  Safety –Gloria Vigliani MD  Alefacept Risk Benefit Profile.

Health Related Quality of Life after serious occupational injuries and long term disability Presenter: Ibishi Nazmie MD,PhD University Clinical Center.

Difficult-to-Treat Psoriasis: Gaining Control of Palmoplantar and Nail Psoriasis.

Patients were considered not in MDA (MDA−) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA+) with a score of 5, 6 or 7 points.

Clinical Trials in IBD.

New Psoriasis Treatments

Primary Care Challenges in Depression - To Treat or Refer?

IL-12 and IL-23.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Treatment Strategies in Mild to Moderate COPD

Optimizing Outcomes in Short Bowel Syndrome With IF

Acute Heart Failure.

Optimizing Use of Biological Agents in Ulcerative Colitis

Introducing JAK Inhibitors in Rheumatoid Arthritis

Best Practices in Huntington Disease

Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

Optimizing Quality of Life and Mental Health in Patients With Psoriasis.

Managing Hereditary Angioedema

Statin Selection in Special Patient Populations: A Case Challenge

The Cancer Pain Journey: Optimizing Identification and Management

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

Complicated Cases in Ulcerative Colitis

Optimal Use of New Fentanyl Formulations for BTCP in Asia

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Psoriasis and Comorbidities Psoriasis and Cardiometabolic Comorbidities.

IL-17 Inhibitors in the Management of Psoriatic Disease

Efficacy of simvastatin in plaque psoriasis: A pilot study

Team-Based Perspectives on Successful Approaches in Treating Obesity

Postpartum Depression

Seizures in the Elderly: Treatment and Special Considerations

Efficacy and Safety of Edoxaban in Patients With AF and HF

Approaches to the Patient With a Runny Nose

Turn to page 26. Read the Conclusion

Understanding Comparative Effectiveness Data in Psoriatic Arthritis

Evolving Treatment Landscape for PsA

ADVANCED PARKINSON'S DISEASE:

Impactful Data in TD That Can Guide Treatment Decisions

Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.

New Data on Emerging Treatments for Psoriasis

Improving Outcomes in Psoriatic Arthritis

Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.

Key Questions for nAMD Treatment Success

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

What's New in Therapeutic Options for Moderate to Severe RA?

After the Baby Comes.

Identifying Strategies for Improving Outcomes in Patients With CTEPH

When Is Intrathecal Drug Delivery Appropriate?

Understanding and Addressing the Needs of Patients With AD

The Multifaceted Nature of Psoriasis Addressing Patients' Needs

Atopic Dermatitis in the Pediatric Practice

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

The Burden of Psoriasis:

Severe Asthma and Comorbidities

Current Challenges in Managing Hemophilia

EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE

Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between.

Clinical Challenges and Updates in Managing Seizure Clusters

When Is Intrathecal Drug Delivery Appropriate?

Targeting IL-23 for Therapeutic Longevity in Psoriasis

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Jennifer L. Hundley, MD, Christie L

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase 3 trials.

Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions

My PAH Patient.

Ask the Psoriasis Expert

Program. The Impact of Treatment Success and Failure in Psoriasis: Implications for Clinical Practice.

Presentation transcript:

Biological Therapy in Psoriasis: Recognizing the Value

Program Objectives

Effects of Stigmatization

Psoriasis Has a Significant Impact on Major Life-Changing Decisions

Five Key Components to CLCI

DLQI

Coping Strategies Mediate the Effects of Psoriasis

Current Treatment Use With Moderate to Severe Psoriasis

Psoriasis and Sexual Behavior

Psoriasis and QoL

Challenges With Assessing the Impact of Psoriasis on QoL

PROs

Characterizing Psoriasis From the Patient’s Perspective

PSI

PSI Total Score

SAPS

Relief From Itching, Scaling and Pain With Biologics as Measured by the PSD

Itch and Psoriasis Treatment

PROs: Summary

Recommendations for Evaluating QoL in Practice

PASI-90 Is Associated With Improved DLQI Outcome

ERASURE/FIXTURE: Psoriasis Skin Clearance is Associated With Patient-Reported Impact

Higher PASI Responses Lead to Greater Improvements in QoL

PASI-90 Is Associated With Improved DLQI Outcome

Absolute PASI Values (Cutoffs: 5, 3, or 2) Might Provide a Better Benchmark

Higher PASI Responses Lead to Greater Improvements in Quality of Life

Results on PASI for Secukinumab 300 mg

Conclusion

Abbreviations

Abbreviations (cont)

Abbreviations (cont)